Merck & Co. Pounces On Moderna mRNA-Based Cancer Vaccine Option

 
• By Jessica Merrill

The company will pay Moderna $250m upfront to develop and commercialize a personalized cancer vaccine for melanoma in combination with Keytruda.

tiger pouncing
Merck exercised an option for Moderna's cancer vaccine • Source: Shutterstock

More from Deals

More from Business